Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide

Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles

DRUG

Adriamycin

Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles

DRUG

Dexamethasone

Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles

Trial Locations (4)

11527

"General Hospital of Athens G. Gennimatas", Athens

11528

"General Hospital of Athens Alexandra", Athens

26504

University General Hospital of Patras, Pátrai

54007

Theageneio Anticancer Hospital of Thessaloniki, Thessaloniki

All Listed Sponsors
lead

Meletios A. Dimopoulos

OTHER

NCT02471820 - Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter